ASCO 2024 | Evaluating the impact of treatment on sexual activity in prostate cancer

Stephen Freedland • 1 Jun 2024

ASCO 2024

EMBARK

Stephen Freedland, MD, Cedars-Sinai Medical Center, Los Angeles, CA, discusses the results of a post hoc analysis of sexual activity (SA) patient-reported outcomes in the EMBARK trial (NCT02319837) on patients with high-risk biochemically recurrent non-metastatic prostate cancer who were sexually active or interested in sex at baseline. Enzalutamide monotherapy was greatly favored to androgen deprivation therapy (ADT), indicating it was better at preserving SA on the whole. Combining enzalutamide to ADT had no impact on most aspects of SA, but may have adversely affected erectile function. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Employment – Genomic Health (I)
Consulting or Advisory Role – A3P Biomedical; Astellas Pharma; AstraZeneca; Bayer; Caper Labs; Clovis Oncology; Dendreon; Exact Sciences; Exosome Diagnostics; Ferring; Hessian Labs; Janssen Biotech; LynxDx; Merck; Myovant Sciences; Pfizer; Sanofi; Tempus
Speakers’ Bureau – AstraZeneca; Sanofi
Research Funding – Bayer (Inst); Diasorin; GenomeDx (Inst); Janssen Biotech (Inst); MDxHealth (Inst); Merck; Myriad Genetics (Inst); OPKO Diagnostics (Inst); Progenika (Inst)
Travel, Accommodations, Expenses – Sanofi